Mereo BioPharma Group PLC ADR (MREO) — Cash Flow Quality Index

Latest as of September 2021: -23.77x

Mereo BioPharma Group PLC ADR (MREO) has a Cash Flow Quality Index of -23.77x as of September 2021. Operating cash flow of $-10.20 Million is below net income of $429.19K, suggesting accrual-heavy earnings not yet converted to cash. Explore how well can Mereo BioPharma Group PLC ADR service its debt to assess how comfortably operating cash covers total debt obligations.

Cash Flow Quality Index

-23.77x
Operating CF / Net Income

Operating Cash Flow

$-10.20 Million
USD

Net Income

$429.19K
USD

Data as of

Sep 2021
Most recent filing

Mereo BioPharma Group PLC ADR Cash Flow Quality Index (2021–2021)

Historical Cash Flow Quality Index for Mereo BioPharma Group PLC ADR across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see Mereo BioPharma Group PLC ADR (MREO) cash flow conversion.

Annual Cash Flow Quality Index for Mereo BioPharma Group PLC ADR (2021–2021)

Year-by-year earnings quality comparison for Mereo BioPharma Group PLC ADR.

Year Quality Index Operating CF (USD) Net Income YoY Change
2021 -0.37x $-7.07 Million $19.22 Million —
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.